

CV Date	22/04/2022
---------	------------

Part A. PERSONAL INFORMATION

First Name *	Elena Manuela		
Family Name *	Reigadas Ramírez		
Sex *	Female	Date of Birth *	24/11/1982
ID number Social Security, Passport *	16075987E	Phone Number *	
URL Web			
Email Address	helenrei@hotmail.com		
Researcher's identification number	Open Researcher and Contributor ID (ORCID) *	0000-0003-0609-1305	
	Researcher ID		
	Scopus Author ID		

* Mandatory

A.1. Current position

Job Title	Facultativo Especialista Adjunto		
Starting date	2015		
Institution	Hospital General Universitario Gregorio Marañón		
Department / Centre	Departamento De Microbiología y Enfermedades Infecciosas / Hospital General Universitario Gregorio Marañón		
Country		Phone Number	
Keywords			

A.2. Previous positions

Period	Job Title / Name of Employer / Country
2013 - 2014	Becario Investigación Río Hortega / Instituto de Salud Carlos III
2012 - 2012	Becario Investigación / Hospital General Universitario Gregorio Marañón
2008 - 2012	Residente Microbiología Clínica / Hospital General Universitario Gregorio Marañón

A.3. Education

Degree/Master/PhD	University / Country	Year
Doctor en Programa Oficial de Posgrado en Ciencias de la Salud y Biomedicina	Universidad Complutense de Madrid	2015

Part C. RELEVANT ACCOMPLISHMENTS

C.1. Publications

AC: corresponding author. (nº x / nº y): position / total authors. If applicable, indicate the number of citations

- Scientific paper.** 2021. Antifungal Susceptibility Testing Identifies the Abdominal Cavity as a Source of Candida glabrata-Resistant Isolates Antimicrobial Agents and Chemotherapy.
- Scientific paper.** 2021. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clinical Microbiology and Infection.
- Scientific paper.** 2020. Clinical impact of a Clostridioides (Clostridium) difficile bedside infectious disease stewardship intervention
- Scientific paper.** 2020. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: experience with lyophilized oral capsules

- 5 **Scientific paper.** Reigadas, E; Bouza, E; Olmedo, M; et al; Munoz, P. 2019. Faecal microbiota transplantation for recurrent *Clostridioides difficile* infection: experience with lyophilized oral capsules. *The Journal of hospital infection*. ISSN 1532-2939. WOS (0)
- 6 **Scientific paper.** Diaz-Garcia, Judith; Alcalá, Luis; Martín-Rabadan, Pablo; et al; Guinea, Jesus. 2019. Susceptibility of uncommon *Candida* species to systemic antifungals by the EUCAST methodology. *Medical mycology*. ISSN 1460-2709. WOS (0)
- 7 **Scientific paper.** Reigadas, E; Alcalá, L; Marín, M; Martín, A; Muñoz, P; Bouza, E; Spanish *C. difficile* Toxin Cycle Study Group. 2019. Prediction of poor outcome in *Clostridioides difficile* infection: A multicentre external validation of the toxin B amplification cycle. *Anaerobe*. pp.102079. ISSN 1095-8274. WOS (0)
- 8 **Scientific paper.** Cusó, L; Reigadas, E; Muñoz, P; Desco, Manuel; Bouza, E. 2019. Evaluation of *Clostridium difficile* Infection with PET/CT Imaging in a Mouse Model. *Molecular imaging and biology*. ISSN 1860-2002. WOS (0)
- 9 **Scientific paper.** Reigadas, E; Vázquez-Cuesta, S; Onori, R; et al; Bouza, E. 2019. *Clostridioides difficile* contamination in the environment of a clinical microbiology laboratory and laboratory workers. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. ISSN 1469-0691. WOS (0)
- 10 **Scientific paper.** Reigadas, Elena; Olmedo, Maria; Valerio, Maricela; Vázquez-Cuesta, Silvia; Alcalá, Luis; Marín, Mercedes; Muñoz, Patricia; Bouza, Emilio. 2018. Fecal microbiota transplantation for recurrent *Clostridium difficile* infection: Experience, protocol, and results *REVISTA ESPAÑOLA DE QUIMIOTERAPIA. SOCIEDAD ESPAÑOLA QUIMIOTERAPIA*. 31-5, pp.411-418. ISSN 0214-3429, ISSN 1988-9518. WOS (1)
- 11 **Scientific paper.** Reigadas, Elena; Alcalá, Luis; Gómez, Javier; Marín, Mercedes; Martín, Adoración; Onori, Raffaella; Muñoz, Patricia; Bouza, Emilio. 2018. Breakthrough *Clostridium difficile* Infection in Cirrhotic Patients Receiving Rifaximin *CLINICAL INFECTIOUS DISEASES*. OXFORD UNIV PRESS INC. 66-7, pp.1086-1091. ISSN 1058-4838, ISSN 1537-6591. WOS (3)
- 12 **Scientific paper.** Reigadas, E.; Muñoz-Pacheco, P.; Vázquez-Cuesta, S.; Alcalá, L.; Marín, M.; Martín, A.; Bouza, E. 2017. Rifaximin-resistant *Clostridium difficile* strains isolated from symptomatic patients *ANAEROBE. ELSEVIER SCI LTD*. 48, pp.269-272. ISSN 1075-9964, ISSN 1095-8274. WOS (2)
- 13 **Scientific paper.** Bouza, E.; Alcalá, L.; Marín, M.; Valerio, M.; Reigadas, E.; Muñoz, P.; González-Del Vecchio, M.; de Egea, V. 2017. An outbreak of *Clostridium difficile* PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy *EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES*. SPRINGER. 36-10, pp.1777-1786. ISSN 0934-9723, ISSN 1435-4373. WOS (6)
- 14 **Scientific paper.** Arboledas JCA; Guerrero IP; Rodríguez MJB; et al; García FG. 2017. Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals. *Diagnostic microbiology and infectious disease*.
- 15 **Scientific paper.** Reigadas, E.; Alcalá, L.; Marín, M.; Martín, A.; Bouza, E. 2017. Clinical, immunological and microbiological predictors of poor outcome in *Clostridium difficile* infection *DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE. ELSEVIER SCIENCE INC*. 88-4, pp.330-334. ISSN 0732-8893, ISSN 1879-0070. WOS (2)
- 16 **Scientific paper.** Alcalá Hernández L; Reigadas Ramírez E; Bouza Santiago E. 2017. *Clostridium difficile* infection. *Medicina clínica*.
- 17 **Scientific paper.** Reigadas, E.; Alcalá, L.; Marín, M.; Martín, A.; Bouza, E. 2017. *C. difficile* PCR-ribotype 023 might go undetected when using ChromID *C. difficile* agar *ANAEROBE. ELSEVIER SCI LTD*. 44, pp.34-35. ISSN 1075-9964, ISSN 1095-8274. WOS (3)
- 18 **Scientific paper.** Alonso, R.; Pérez-García, F.; Ampuero, D.; Reigadas, E.; Bouza, E. 2017. New direct-acting antivirals for patients with chronic HCV infection: can we monitor treatment using an HCV core antigen assay? *DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE. ELSEVIER SCIENCE INC*. 87-3, pp.243-246. ISSN 0732-8893, ISSN 1879-0070. WOS (6)

- 19 **Scientific paper.** Reigadas, E.; Alcalá, L.; Valerio, M.; Marín, M.; Martín, A.; Bouza, E. 2016. Toxin B PCR cycle threshold as a predictor of poor outcome of *Clostridium difficile* infection: a derivation and validation cohort study JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. OXFORD UNIV PRESS. 71-5, pp.1380-1385. ISSN 0305-7453, ISSN 1460-2091. WOS (18)
- 20 **Scientific paper.** Reigadas E; Alcalá L; Marín M; Muñoz-Pacheco P; Catalán P; Martín A; Bouza E. 2016. Clinical significance of direct cytotoxicity and toxigenic culture in *Clostridium difficile* infection. Anaerobe.
- 21 **Scientific paper.** Bouza E; Del Vecchio MG; Reigadas E. 2016. Spectrum of *Clostridium difficile* infections: Particular clinical situations. Anaerobe.
- 22 **Scientific paper.** Reigadas, E.; Alcalá, L.; Marín, M.; Martín, A.; Iglesias, C.; Bouza, E. 2016. Role of binary toxin in the outcome of *Clostridium difficile* infection in a non-027 ribotype setting EPIDEMIOLOGY AND INFECTION. CAMBRIDGE UNIV PRESS. 144-2, pp.268-273. ISSN 0950-2688, ISSN 1469-4409. WOS (13)
- 23 **Scientific paper.** Alcalá, L.; Reigadas, E.; Marín, M.; Martín, A.; Catalán, P.; Bouza, E.; Spanish *Clostridium Difficile*. 2015. Impact of clinical awareness and diagnostic tests on the underdiagnosis of *Clostridium difficile* infection EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. SPRINGER. 34-8, pp.1515-1525. ISSN 0934-9723, ISSN 1435-4373. WOS (27)
- 24 **Scientific paper.** Reigadas, E.; Alcalá, L.; Marín, M.; Peláez, T.; Martín, A.; Iglesias, C.; Bouza, E. 2015. In vitro activity of surtomycin against contemporary clinical isolates of toxigenic *Clostridium difficile* strains obtained in Spain JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. OXFORD UNIV PRESS. 70-8, pp.2311-2315. ISSN 0305-7453, ISSN 1460-2091. WOS (9)
- 25 **Scientific paper.** Bouza, E.; Rodríguez-Creixems, M.; Alcalá, L.; Marín, M.; De Egea, V.; Braojos, F.; Muñoz, P.; Reigadas, E. 2015. Is *Clostridium difficile* infection an increasingly common severe disease in adult intensive care units? A 10-year experience JOURNAL OF CRITICAL CARE. W B SAUNDERS CO-ELSEVIER INC. 30-3, pp.543-549. ISSN 0883-9441, ISSN 1557-8615. WOS (15)
- 26 **Scientific paper.** Reigadas, E.; Alcalá, L.; Marín, M.; Burillo, A.; Muñoz, P.; Bouza, E. 2015. Missed diagnosis of *Clostridium difficile* infection; a prospective evaluation of unselected stool samples JOURNAL OF INFECTION. W B SAUNDERS CO LTD. 70-3, pp.264-272. ISSN 0163-4453, ISSN 1532-2742. WOS (9)
- 27 **Scientific paper.** Reigadas, E.; Rodríguez-Creixems, M.; Sánchez-Carrillo, C.; Martín-Rabadán, P.; Bouza, E. 2015. Uncommon aetiological agents of catheter-related bloodstream infections EPIDEMIOLOGY AND INFECTION. CAMBRIDGE UNIV PRESS. 143-4, pp.741-744. ISSN 0950-2688, ISSN 1469-4409. WOS (3)
- 28 **Scientific paper.** Marín, Mercedes; Martín, Adoración; Alcalá, Luis; Cercenado, Emilia; Iglesias, Cristina; Reigadas, Elena; Bouza, Emilio. 2015. *Clostridium difficile* Isolates with High Linezolid MICs Harbor the Multiresistance Gene *cfr* ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. AMER SOC MICROBIOLOGY. 59-1, pp.586-589. ISSN 0066-4804, ISSN 1098-6596. WOS (35)
- 29 **Scientific paper.** Alcalá, Luis; Reigadas, Elena; Marín, Mercedes; Fernández-Chico, Antonia; Catalán, Pilar; Bouza, Emilio. 2015. Comparison of GenomEra C. *difficile* and Xpert C. *difficile* as Confirmatory Tests in a Multistep Algorithm for Diagnosis of *Clostridium difficile* Infection JOURNAL OF CLINICAL MICROBIOLOGY. AMER SOC MICROBIOLOGY. 53-1, pp.332-335. ISSN 0095-1137, ISSN 1098-660X. WOS (11)
- 30 **Scientific paper.** Bouza, E.; Eworo, A.; Fernández Cruz, A.; Reigadas, E.; Rodríguez-Creixems, M.; Muñoz, P. 2013. Catheter-related bloodstream infections caused by Gram-negative bacteria JOURNAL OF HOSPITAL INFECTION. W B SAUNDERS CO LTD. 85-4, pp.316-320. ISSN 0195-6701, ISSN 1532-2939. WOS (14)
- 31 **Scientific paper.** Bouza, Emilio; Marín, Mercedes; Peláez, Teresa; Alcalá, Luis; Spanish Soc Chemotherapy. 2013. The situation and management of *Clostridium difficile* infection in Spain: an opinion document REVISTA ESPAÑOLA DE QUIMIOTERAPIA. SOCIEDAD ESPAÑOLA QUIMIOTERAPIA. 26-3, pp.261-286. ISSN 0214-3429, ISSN 1988-9518. WOS (8)

- 32 **Scientific paper.** Pelaez, Teresa; Alcalá, Luis; Blanco, Jose L.; et al; Bouza, Emilio. 2013. Characterization of swine isolates of *Clostridium difficile* in Spain: A potential source of epidemic multidrug resistant strains? ANAEROBE. ELSEVIER SCI LTD. 22, pp.45-49. ISSN 1075-9964, ISSN 1095-8274. WOS (35)
- 33 **Scientific paper.** Reigadas, E.; Rodríguez-Creixems, M.; Guembe, M.; Sánchez-Carrillo, C.; Martín-Rabadán, P.; Bouza, E. 2013. Catheter-related bloodstream infection caused by *Enterococcus* spp. CLINICAL MICROBIOLOGY AND INFECTION. ELSEVIER SCI LTD. 19-5, pp.457-461. ISSN 1198-743X, ISSN 1469-0691. WOS (10)
- 34 Machado, Marina; Valerio, Maricela; Álvarez-Uría, Ana; et al; COVID-19 Study Grp. 2021. Invasive pulmonary aspergillosis in the COVID-19 era: An expected new entity MYCOSES. 64. ISSN 0933-7407. WOS (4) <https://doi.org/10.1111/myc.13213>
- 35 Díaz-García, Judith; Mesquida, Aina; Sánchez-Carrillo, Carlos; Reigadas, Elena; Muñoz, Patricia; Escribano, Pilar; Guinea, Jesus. 2021. Monitoring the Epidemiology and Antifungal Resistance of Yeasts Causing Fungemia in a Tertiary Care Hospital in Madrid, Spain: Any Relevant Changes in the Last 13 Years? ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 65. ISSN 0066-4804. <https://doi.org/10.1128/AAC.01827-20>
- 36 Davies, Kerrie; Davis, Georgina; Barbut, Frederic; et al; Wilcox, Mark H. 2020. Factors affecting reported *Clostridioides difficile* infection rates; the more you look the more you find, but should you believe what you see? ANAEROBE. 62. ISSN 1075-9964. WOS (2) <https://doi.org/10.1016/j.anaerobe.2020.102178>
- 37 Freeman, Jane; Vernon, Jonathan; Pilling, Sally; et al; Pan European Longitudinal Survei. 2020. Five-year Pan-European, longitudinal surveillance of *Clostridium difficile* ribotype prevalence and antimicrobial resistance: the extended ClosER study EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. 39. ISSN 0934-9723. WOS (5) <https://doi.org/10.1007/s10096-019-03708-7>
- 38 Guinea, Jesus; Arendrup, Maiken C.; Canton, Rafael; et al; Escribano, Pilar. 2020. Genotyping Reveals High Clonal Diversity and Widespread Genotypes of *Candida* Causing Candidemia at Distant Geographical Areas FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY. 10. ISSN 2235-2988. WOS (1) <https://doi.org/10.3389/fcimb.2020.00166>
- 39 Reigadas, E.; Vázquez-Cuesta, S.; Villar-Gomara, L.; Onori, R.; Alcalá, L.; Marín, M.; Muñoz, P.; Bouza, E. 2020. Role of *Clostridioides difficile* in hospital environment and healthcare workers ANAEROBE. 63. ISSN 1075-9964. <https://doi.org/10.1016/j.anaerobe.2020.102204>
- 40 Bouza, Emilio; Aguado, Jose Maria; Alcalá, Luis; et al; Barberán, Jose. 2020. Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR) REVISTA ESPANOLA DE QUIMIOTERAPIA. 33. ISSN 0214-3429. <https://doi.org/10.37201/req/2065.2020>
- 41 Díaz-García, Judith; Alcalá, Luis; Martín-Rabadán, Pablo; et al; Guinea, Jesus. 2020. Susceptibility of uncommon *Candida* species to systemic antifungals by the EUCAST methodology MEDICAL MYCOLOGY. 58. ISSN 1369-3786. WOS (1) <https://doi.org/10.1093/mmy/myz121>
- 42 Olmedo, Maria; Alcalá, Luis; Valerio, Maricela; Marín, Mercedes; Onori, Raffaella; Reigadas, Elena; Muñoz, Patricia; Bouza, Emilio. 2020. Three different patterns of positive *Clostridium difficile* laboratory tests. A comparison of clinical behavior DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE. 97. ISSN 0732-8893. <https://doi.org/10.1016/j.diagmicrobio.2020.115050>
- 43 Olmedo, Maria; Reigadas, Elena; Valerio, Maricela; Vázquez-Cuesta, Silvia; Antonio Pajares, Jose; Matilla, Ana; Muñoz, Patricia; Bouza, Emilio. 2019. Is it reasonable to perform Fecal Microbiota Transplantation for recurrent *Clostridium difficile* Infection in patients with liver cirrhosis? REVISTA ESPANOLA DE QUIMIOTERAPIA. 32-2, pp.205-207. ISSN 0214-3429, ISSN 1988-9518. WOS (0)

C.3. Research projects and contracts

- 1 Project.** PI13/00687. Evolución de la Prevalencia, Diagnostico, Caracterización Fenotípica y Genotípica de la Infección por *C. difficile* (ICD) en España. Factores de Riesgo de Recurrencia y Valor del PET-TAC en la ICD.. Elena MANuela Reigadas Ramírez. 01/01/2014-2018. 216,71 €.
- 2 Project.** PI20/01381 The role of the microbiome as a diagnostic, prognostic and therapeutic tool in *C. difficile* infection and other diseases. From 01/01/2021. 196.020 €.
- 3 Project.** PI17/00061 Influencia de la gripe en los eventos cardiacos agudos y busqueda de virus gripales cardiotrópicos. Estudio INFLUCAR. From 01/01/2018.
- 4 Project.** PI16/00490 Desarrollo de un Biobanco de microbiota intestinal humana para programas de intervención precoz en el control de la Infección por. Elena Manuela Reigadas Ramírez. From 01/01/2017. 110.000 €.
- 5 Project.** PI16/02037 Diagnóstico de la bacteriemia por Gram positivos mediante nuevos trazadores PET selectivos. From 01/01/2017.
- 6 Project.** PIE16/00055 The microbiome as a target for precision medicine. A frontier exploration from established to innovative indications. From 01/01/2017. 493.625 €.
- 7 Contract.** Incidence, Clinical Characteristics, Strain Characterization and Evolution of *Clostridium difficile* Infection (CDI) in Hematologic Patients Merck Sharp & Dohme España, S.A.. Reigadas E. 01/01/2019-01/01/2021. 30.000 €.
- 8 Contract.** CONTRATO DE TRASFERENCIA DE KNOW-HOW Y LICENCIA ENTRE LA FUNDACIÓN PARA LA INVESTIGACIÓN BIOMÉDICA DEL HOSPITAL GREGORIO MARAÑÓN Y LA ENTIDAD MERCANTIL MIKROBIOMIK HEALTHCARE COMPANY S.L 01/06/2018-01/07/2019. 50.000 €.
- 9 Contract.** COMBACTE-CDI "Combating bacterial resistance in Europe- *Clostridium difficile* Infections" UNIVERSITY OF LEEDS. ELENA MANUELA REIGADAS RAMIREZ. From 15/04/2018. 71.400 €.
- 10 Contract.** CLOVER Pfizer B5091007 A Phase 3, Placebo-controlled, Randomized, Observer-blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A *Clostridium difficile* Vaccine In Adults 50 Years Of Age And Older" Pfizer, S.A.. From 2018.
- 11 Contract.** Assessment of de Incidence of *Clostridium difficile* Infections in hospitalised Patients on Antibiotic Treatment (ANTICIPATE) UNIVERSITY MEDICAL CENTER UTRECHT. EMILIO BOUZA SANTIAGO. From 07/08/2017. 14.110 €.
- 12 Contract.** MSD-CDI-2016-01 "Determinación del coste de la recurrencia por *Clostridium difficile* en pacientes adultos tratados en hospitales españoles. Estudio observacional retrospectivo multicéntrico." Merck Sharp & Dohme España, S.A.. From 2017.
- 13 Contract.** "Estudio Europeo, Longitudinal European *Clostridium difficile* Infection Diagnosis Surveillance Study (LUCID)" University of Leeds. 2015-01/01/2017.
- 14 Contract.** Ensayo Clínico Internacional para comparar cadazolid frente a vancomicina en el tratamiento de diarrea asociada a *Clostridium difficile* (DADC) ACTELION PHARMACEUTICALS, LTD. EMILIO BOUZA SANTIAGO. 23/04/2014-18/09/2017. 36.850 €.
- 15 Contract.** ESTUDIO ALEATORIZADO, DOBLE CIEGO, CON CONTROL ACTIVO DEL CB-183,315 EN PACIENTES CON DIARREA ASOCIADA A *CLOSTRIDIUM DIFFICILE*. CUBIST PHARMACEUTICAL INC. EMILIO BOUZA SANTIAGO. 03/04/2013-18/04/2015. 26.445 €.
- 16 Contract.** ESTUDIO ASTELLAS PHARMA, ESTUDIO ICD"INCIDENCIA, FACTORES DE RIESGO Y EVOLUCIÓN DE LA INFECCIÓN POR *CLOSTRIDIUM DIFFICILE* (ICD) EN UNIDADES DE CUIDADOS INTENSIVOS DE ADULTOS". Astellas. EMILIO BOUZA SANTIAGO. 25/02/2013-25/09/2015. 10.000 €.
- 17 Contract.** CONTRATO CON ASTELLAS PHARMA Y DR BOUZA PARA LA REALIZACIÓN DEL ESTUDIO TITULADO "ESTUDIO DE LA INFECCIÓN POR *CLOSTRIDIUM DIFFICILE*: INCIDENCIA, EPIDEMIOLOGÍA, CARACTERÍSTICAS CLÍNICAS, FACTORES DE RIESGO DE GRAVEDAD Y RECURRENCIA", EN INGLÉS "RISK FACTORS OF SEVERE INFECTION AND RECURRENCES, CHARACTERIZATION OF TOXIGENIC ISOLATES OF *CLOSTRIDIUM DIFFICILE*". Astellas Pharma , S.A.. EMILIO BOUZA SANTIAGO. 14/01/2013-10/10/2014. 0 €.

- 18 Contract.** FID-EC-0001 "Estudio aleatorizado, doble ciego y controlado, comparativo de la eficacia de Fidaxomicina versus Vancomicina en la curación clínica sostenida de la infección por *C. difficile* en adultos que reciben tratamiento inmunosupresor." Astellas. From 2013.
- 19 Contract.** CONTRATO CON UNIVERSIDAD DE LEEDS, ESTUDIO EUCLIDEUROPEAN, MULTI-CENTRE, PROSPETIVE BI-ANNUAL POINT PREVALENCE STUDY OF CLOSTRIDIUM DIFFICILE INFECTION IN HOSPITALIZED PATIENTS WITH DIARRHEA (EUCLID). University of Leeds. EMILIO BOUZA SANTIAGO. 26/10/2012-18/11/2013. 90.387,95 €.
- 20 Contract.** "ESTUDIO DE FASE III ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO, DE LA EFICACIA, LA SEGURIDAD Y LA TOLERABILIDAD DE UNA SOLA INFUSIÓN DE MK-6072 (ANTICUERPO MONOCLONAL HUMANO CONTRA LA TOXINA B DE *C. DIFFICILE*) Y MK Merck Sharp & Dohme España, S.A.. EMILIO BOUZA SANTIAGO. 16/07/2012-05/06/2015. 141.082 €.
- 21 Contract.** Pan-European Longitudinal Surveillance of Antibiotic Resistance among prevalent *Clostridium difficile* ribotypes (CLOSER) University of Leeds. 2012-01/01/2017.